In regards to the safety of G-CSF on the developing embryo, several studies have looked into the effects of G-CSF in pregnant patients with cancer and found no significant difference in teratogenicity between patients prescribed G-CSF and individuals not prescribed G-CSF, thereby indicating that G-CSF had no teratogenic effect on the developing fetus (Zeidler et al., 2014; Boxer et al., 2015; Gurevich-Shapiro & Avivi, 2019; Cardonick et al., 2012). The gene discussed is CSF3; the disease is cancer.